CFM
IOVA icon

Catalyst Funds Management’s Iovance Biotherapeutics IOVA Stock Holding History

Catalyst Funds Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,400
Closed -$347K – 1366
2024
Q1 		$347K Buy
+23,400
New +$272K 0.1% 171

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Catalyst Funds Management's IOVA Position: Q2 2024 in Review

Catalyst Funds Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 23,400 shares — an estimated $347K sold.

Catalyst Funds Management first reported a position in IOVA in Q1 2024 and held it in 1 quarter. The position peaked at $347K in Q1 2024. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • Catalyst Funds Management reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 23,400 Iovance Biotherapeutics shares in Q2 2024, an estimated $347K.
  • Catalyst Funds Management first reported a position in Iovance Biotherapeutics in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Iovance Biotherapeutics position peaked at $347K in Q1 2024.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.